GLUCOTRACK ANNOUNCES NEW VICE PRESIDENT OF CLINICAL OPERATIONS
Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on diabetes management, has announced the appointment of Sandie Martha as Vice President of Clinical Operations. With over 20 years of experience in clinical research, Martha brings expertise in leading global clinical trials for glucose monitoring and cardiology. Her role will be important in executing Glucotrack's Clinical Trial Program for their Continuous Blood Glucose Monitor (CBGM).
Martha's extensive background includes leadership positions at Glysens, Dexcom, and Truvian, where she managed various aspects of clinical trials and regulatory submissions. Her appointment is seen as a strategic move to advance Glucotrack's CBGM technology through clinical trials and ultimately bring it to market for millions of people living with diabetes.
Glucotrack, Inc. (Nasdaq: GCTK), un'azienda di tecnologia medica focalizzata sulla gestione del diabete, ha annunciato la nomina di Sandie Martha a Vicepresidente delle Operazioni Cliniche. Con oltre 20 anni di esperienza nella ricerca clinica, Martha porta con sé competenze nella conduzione di studi clinici globali per il monitoraggio della glucosio e la cardiologia. Il suo ruolo sarà fondamentale per l'esecuzione del Programma di Studi Clinici di Glucotrack per il loro Monitoraggio Continuo della Glucosio nel Sangue (CBGM).
Il vasto background di Martha include ruoli di leadership presso Glysens, Dexcom e Truvian, dove ha gestito diversi aspetti degli studi clinici e delle sottomissioni regolatorie. La sua nomina è vista come una mossa strategica per far avanzare la tecnologia CBGM di Glucotrack attraverso studi clinici e portarla infine sul mercato per milioni di persone che vivono con il diabete.
Glucotrack, Inc. (Nasdaq: GCTK), una empresa de tecnología médica centrada en la gestión de la diabetes, ha anunciado el nombramiento de Sandie Martha como Vicepresidenta de Operaciones Clínicas. Con más de 20 años de experiencia en investigación clínica, Martha aporta experiencia en la conducción de ensayos clínicos globales para el monitoreo de glucosa y cardiología. Su rol será importante en la ejecución del Programa de Ensayos Clínicos de Glucotrack para su Monitor Continuo de Glucosa en Sangre (CBGM).
El extenso historial de Martha incluye cargos de liderazgo en Glysens, Dexcom y Truvian, donde gestionó varios aspectos de ensayos clínicos y presentaciones regulatorias. Su nombramiento se considera un movimiento estratégico para avanzar en la tecnología CBGM de Glucotrack a través de ensayos clínicos y, en última instancia, llevarla al mercado para millones de personas que viven con diabetes.
Glucotrack, Inc. (Nasdaq: GCTK), 당뇨병 관리에 중점을 둔 의료 기술 회사가 Sandie Martha를 임상 운영 부사장으로 임명했다고 발표했습니다. 20년 이상의 임상 연구 경험을 가진 Martha는 포도당 모니터링 및 심장학을 위한 글로벌 임상 시험을 주도하는 전문성을 가지고 있습니다. 그녀의 역할은 Glucotrack의 지속적인 혈당 모니터 (CBGM)을 위한 임상 시험 프로그램을 실행하는 데 중요할 것입니다.
Martha의 폭넓은 경력에는 Glysens, Dexcom 및 Truvian에서의 리더십 직책이 포함되어 있으며, 그곳에서 그녀는 임상 시험 및 규제 제출의 다양한 측면을 관리했습니다. 그녀의 임명은 Glucotrack의 CBGM 기술을 임상 시험을 통해 발전시키고 궁극적으로 당뇨병 환자 수백만 명을 위해 시장에 출시하는 전략적 조치로 간주됩니다.
Glucotrack, Inc. (Nasdaq: GCTK), une entreprise de technologie médicale axée sur la gestion du diabète, a annoncé la nomination de Sandie Martha en tant que Vice-Présidente des Opérations Cliniques. Forte de plus de 20 ans d'expérience dans la recherche clinique, Martha apporte son expertise dans la direction d'essais cliniques mondiaux pour la surveillance de la glucosurie et la cardiologie. Son rôle sera important dans l'exécution du Programme d'Essai Clinique de Glucotrack pour leur Moniteur Continu de Glucose dans le Sang (CBGM).
Le parcours impressionnant de Martha comprend des postes de direction chez Glysens, Dexcom et Truvian, où elle a géré divers aspects des essais cliniques et des soumissions réglementaires. Sa nomination est perçue comme un mouvement stratégique visant à faire avancer la technologie CBGM de Glucotrack par le biais d'essais cliniques et à l'amener finalement sur le marché pour des millions de personnes vivant avec le diabète.
Glucotrack, Inc. (Nasdaq: GCTK), ein Medizintechnologieunternehmen, das sich auf das Diabetesmanagement konzentriert, hat die Ernennung von Sandie Martha zur Vizepräsidentin der klinischen Operationen bekannt gegeben. Mit über 20 Jahren Erfahrung in der klinischen Forschung bringt Martha Expertise in der Leitung globaler klinischer Studien für die Glukoseüberwachung und Kardiologie mit. Ihre Rolle wird entscheidend sein, um das klinische Studienprogramm von Glucotrack für ihren Kontinuierlichen Blutzucker-Monitor (CBGM) umzusetzen.
Marthas umfangreicher Hintergrund umfasst Führungspositionen bei Glysens, Dexcom und Truvian, wo sie verschiedene Aspekte klinischer Studien und regulatorischer Einreichungen geleitet hat. Ihre Ernennung wird als strategischer Schritt angesehen, um die CBGM-Technologie von Glucotrack durch klinische Studien voranzubringen und schließlich Millionen von Menschen mit Diabetes auf den Markt zu bringen.
- Appointment of experienced Vice President of Clinical Operations with 20+ years in the field
- Strategic expertise in global clinical trials for glucose monitoring and cardiology
- Potential advancement of CBGM technology through clinical trials
- None.
Glucotrack expands leadership team with clinical trial expertise for the continuous blood glucose monitor for people with diabetes
Rutherford, NJ, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that Sandie Martha has joined the Company as Vice President of Clinical Operations.
“Sandie brings a wealth of knowledge and expertise to the team in leading clinical trials for both glucose monitoring and cardiology.” said Paul Goode, PhD, President and CEO of Glucotrack. “The breadth and depth of her experience leading global clinical trials will be invaluable, and we are excited to have her join our team as we embark on Continuous Blood Glucose Monitor (CBGM) human clinical trials to ultimately bring this technology to market for the millions of people living with diabetes.”
Ms. Martha brings over 20 years of clinical research experience in both medical technology and drug development, leading all aspects of clinical trials including protocol development and execution, clinical site training and monitoring, and regulatory submissions. Ms. Martha brings an impressive track record of strategic planning and successful delivery of clinical trials to quickly advance products through the clinical lifecycle. She previously served as Vice President of Clinical Affairs at Glysens, where she led planning and execution for domestic and international clinical trials for an implantable continuous glucose monitor. Her background also includes clinical operations roles in continuous glucose monitoring with Dexcom, in-hospital glucose monitoring with Luminous Medical and cardiology with Intersection Medical. Her most recent clinical role was with Truvian, an automated benchtop platform that enables comprehensive routine blood testing. Ms. Martha holds a Master of Science in Physiology from San Diego State University and a Bachelor of Science in Biological Sciences from the University of Miami.
Ms. Martha will be responsible for executing the company’s Clinical Trial Program including strategic partnering with CROs, clinical centers and investigators, developing and executing clinical protocols, and managing the monitoring and analysis of data for clinical study reports for regulatory agency submissions for the Company’s CBGM.
“Having seen loved ones struggle with their diabetes management, I am passionate about the potential for advanced glucose monitoring technologies. The real-time continuous blood glucose data provided by Glucotrack’s CBGM offers a less intrusive approach to glucose monitoring for extended periods of time, enabling people to live less encumbered by the hassles of traditional glucose monitoring approaches. I am thrilled to join the Glucotrack leadership team in bringing this innovative technology to people with diabetes,” said Ms. Martha.
For more information about Glucotrack’s CBGM, visit glucotrack.com.
# # #
About Glucotrack, Inc.
Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes.
Glucotrack’s CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 2+ years, no on-body wearable component and with minimal calibration. For more information, please visit http://www.glucotrack.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “believe”, “expect”, “plan” and “will” are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Readers are cautioned that certain important factors may affect Glucotrack’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Glucotrack’s results include, but are not limited to, the ability of Glucotrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including U.S. Food and Drug Administration approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to Glucotrack’s future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Glucotrack’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2023 as filed with the SEC on March 28, 2024.
Contacts:
Investor Relations:
investors@glucotrack.com
Media:
GlucotrackPR@icrinc.com
FAQ
Who is Glucotrack's new Vice President of Clinical Operations?
What is Glucotrack (GCTK) developing?
What will be Sandie Martha's main responsibilities at Glucotrack (GCTK)?
What is Glucotrack's (GCTK) stock symbol and where is it traded?
